吉西他滨联合长春瑞滨方案一线治疗中国晚期非小细胞肺癌患者的多中心回顾性研究

BACKGROUND AND OBJECTIVE: Chemotherapy has become the mainstay of first-line therapy. Non-platinum containing drugs are characterized by favorable toxicity profiles and is better tolerated than platinum-based regimens. The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. METHODS: We retrospectively reviewed 67 NSCLC patients treated with this agent at five Hospital in China from Jan 2004 to Jun 2010. Survival analysis was evaluated by Kaplan-Meier method, multivariate analyses were performed to find prognostic markers using Cox proportional hazards model. RESULTS: A total of 67 patients were analyzed in this study. There were 52 patients with RRM1 negative and ERCC1 positive. The objective response rate was 34.3%. The disease control rate was 76.1%. The progression-free survival and median overall survival was 5.5 and 22.1 months, respectively. On multivariate analysis, performance status score and whether further treatment were independent prognostic factor for overall survival. CONCLUSION: The GN agent is effective for the first line treatment in advanced non-small cell lung cacer. The toxicity is well tolerated.